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OBJECTIVES: To evaluate impact of TNF-alfa inhibitors reim-
bursement (adalimumab, etanercept and inﬂiximab) in the treat-
ment of ankylosing spondylitis (AS) on Polish National Heath
Fund’s budget. METHODS: Budget impact from the perspective
of public payer (National Heath Fund) in the 3 years time
horizon was constructed. The number of patients eligible for
treatment was estimated based on epidemiological data on AS
prevalence from other European countries and statement of
polish experts on minimal availability of biological treatment in
Poland (0.4% of AS patients). Costs analyzed: acquisition costs
of drugs, drug administration and treatment monitoring costs,
adverse events treatment costs including tuberculosis monitoring
and treatment costs, and AS hospitalization costs. Health out-
comes included quality-adjusted life-year (QALY) and were esti-
mated based on date from systematic review and economic
analysis. Multiple sensitivity and scenario analyses were per-
formed. Values are presented in PLN (exchange rate: 1
Euro = 3.40 PLN). RESULTS: In base scenario 184 AS patients
were eligible for TNF-alfa inhibitors treatment annually. Assum-
ing equal market share between adalimumab, etanercept and
inﬂiximab total one year treatment cost after market share
stabilization were calculated for 10.63 mln PLN and comprised
3.38 and 3.87 mln PLN for adalimumab, etanercept and
inﬂiximab-based treatments, respectively. Total 3-years treatment
costs assuming one year time to cover target population and
2-years time to reach market share stabilization was 27.72mln
PLN. Incremental annual cost while comparing base scenario
with worse scenario (all patients treated only with standard care
and no TNF-alfa inhibitors) ranged from 5.86 to 10.43 mln PLN.
Corresponding health beneﬁt represented annual increase in
QALY of 90 to 118 years. CONCLUSIONS: The impact of
TNF-alfa inhibitors on Polish National Heath Fund’s budget for
limited to less than 200 patients population is marginal.
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OBJECTIVES: Recent evidence has demonstrated a link between
disease severity in rheumatoid arthritis and overall non-drug
costs to the health care payer. This analysis aims to estimate
the likely lifetime cost savings associated with achieving better
clinical response in patients treated with etanercept, compared
against rituximab after the failure of two previous DMARD
therapies. METHODS: An existing economic model was repopu-
lated using data linking resource use with disease severity, as
measured by the Health Assessment Questionnaire (HAQ). The
model uses Markov techniques to predict the lifetime health
outcomes associated with different treatments for patients with
RA in the UK. For each treatment in the model, the initial (ﬁrst
six months), medium-term (six to thirty-six months) and long-
term (after thirty-six months) effects on the Health Assessment
Questionnaire (HAQ) score were calculated. HAQ scores at each
time period determined each patient’s utility (QALYs), resource
use and mortality. Effectiveness data were derived from the
results from the TEMPO trial and published literature. Utility
scores were converted from HAQ data using the EQ-5D. Unit
cost data were drawn from established national databases, and
were multiplied by resource use to predict the total cost for each
cohort. RESULTS: When the impact of HAQ on resource was
not included in the model, the incremental cost of the etanercept
arm was estimated to be £4648 over the patient’s lifetime. When
resource use was linked with response to treatment, the incre-
mental cost fell to £3304 (a reduction of 29%). Because the
incremental effectiveness of etanercept would remain unchanged,
the incremental cost-effectiveness ratio would also be reduced by
29%. CONCLUSIONS: By incorporating a link between HAQ
and resource use into an existing economic model, it has been
established that a substantial proportion of a treatment’s incre-
mental cost may be offset by reduced use of resources in other
areas.
PMS18
COSTS OFTREATMENT OF RHEUMATOID ARTHRITIS WITH
BIOLOGICAL DRUGS
Rasmussen C1, Knudsen MS2, Hansen BB2, Lindkvist RM3
1Vendsyssel Hospital, Hjørring, Denmark, 2COWI, Lyngby, Denmark,
3Wyeth Denmark, Glostrup, Denmark
OBJECTIVES: Biological drugs, which are used for the treatment
of severe rheumatoid arthritis (RA), have high unit costs. This
has caused attention to the choice between the available biologi-
cal drugs at Danish hospitals. The ofﬁcial list unit costs can be
misleading if clinically indicated dose escalation or treatment
breaks affect the total consumption of the drug. The purpose of
this study was to compare the actual costs of treatment of RA
with the three most commonly used biological drugs (inﬂiximab,
etanercept and adalimumab) at Danish hospitals. METHODS:
The study is a cost-minimization analysis designed as a retrospec-
tive cohort study using data from medical records (n = 198).
Data was collected at three Danish hospitals. Consumption of
biological drugs was measured during a 12 months period.
Regression analysis was used to analyze the inﬂuence from
patient characteristics on the dosage of inﬂiximab. Breaks in the
treatment with etanercept and adalimumab were measured from
pharmacy records at one hospital. RESULTS: The average
annual costs of inﬂiximab vary due to dose escalation from
€10,546 at one hospital to €16,109 at another hospital. Regres-
sion analysis show that dose escalation of inﬂiximab is positively
associated with pain index (DAS28) and duration of therapy.
The average annual costs of etanercept and adalimumab were
€13,321 (both drugs) after adjustment for treatment breaks,
which accounted for 20% of the time at one hospital. CONCLU-
SIONS: Real-life medicine expenses for treatment of RA with
inﬂiximab, etanercept and adalimumab tend to be equal due to
dose escalation of inﬂiximab and treatment breaks with etaner-
cept and adalimumab. Consequently, the choice of drug can be
based on considerations of efﬁcacy, safety, patient needs and the
feasibility of the treatment.
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OBJECTIVES: To compare the cost-effectiveness ratios of etan-
ercept in ﬁrst line to etanercept in second line, together with
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